Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors
出版年份 2021 全文链接
标题
Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors
作者
关键词
-
出版物
Cancer Management and Research
Volume Volume 13, Issue -, Pages 7623-7636
出版商
Informa UK Limited
发表日期
2021-10-04
DOI
10.2147/cmar.s267220
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia
- (2021) Kiril Trpkov et al. MODERN PATHOLOGY
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
- (2021) Elio Adib et al. CLINICAL CANCER RESEARCH
- A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma
- (2021) Thomas E. Hutson et al. EUROPEAN UROLOGY
- Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
- (2021) Katrina S. Pedersen et al. INVESTIGATIONAL NEW DRUGS
- Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
- (2020) Kazuki Kuroshima et al. CANCER SCIENCE
- The multifaceted role of reactive oxygen species in tumorigenesis
- (2020) Anuradha Kirtonia et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Immunotherapy in Renal Cell Carcinoma: The Future Is Now
- (2020) Antoine Deleuze et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors
- (2020) Mojun Zhu et al. INVESTIGATIONAL NEW DRUGS
- Prognostic significance of PI3K/AKT/ mTOR signaling pathway members in clear cell renal cell carcinoma
- (2020) Demin Fan et al. PeerJ
- Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma
- (2020) Xinan Sheng et al. EBioMedicine
- Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study)
- (2020) Alejo Rodriguez-Vida et al. BJU INTERNATIONAL
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
- (2020) Robert J. Motzer et al. CANCER
- Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
- (2020) Martin H. Voss et al. BRITISH JOURNAL OF CANCER
- Systemic Therapies for the Management of Non–Clear Cell Renal Cell Carcinoma: What Works, What Doesn’t, and What the Future Holds
- (2020) Panagiotis Zoumpourlis et al. Clinical Genitourinary Cancer
- Autophagy inhibition to augment mTOR inhibition: A phase I/II trial of everolimus and hydroxychloroquine in patients with previously treated renal cell carcinoma
- (2019) Naomi B. Haas et al. CLINICAL CANCER RESEARCH
- PTEN expression and mutations in TSC1 , TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma
- (2019) Juan M. Roldan‐Romero et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma
- (2019) Anthony Wood et al. INVESTIGATIONAL NEW DRUGS
- Clinical development of mTor inhibitors for renal cancer
- (2017) Michele Ghidini et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer
- (2017) Geert A. Cirkel et al. JAMA Oncology
- Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
- (2016) D. J. Kwiatkowski et al. CLINICAL CANCER RESEARCH
- Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis
- (2016) Bernard Escudier et al. EUROPEAN JOURNAL OF CANCER
- A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
- (2016) Thomas Powles et al. EUROPEAN UROLOGY
- Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
- (2016) Nizar M. Tannir et al. EUROPEAN UROLOGY
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2016) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
- (2016) Andrew J Armstrong et al. LANCET ONCOLOGY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
- (2016) Vanessa S. Rodrik-Outmezguine et al. NATURE
- A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
- (2016) Maria I. Carlo et al. ONCOLOGIST
- EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma
- (2015) I. D. Davis et al. ANNALS OF ONCOLOGY
- RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
- (2015) A. Ravaud et al. ANNALS OF ONCOLOGY
- First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014
- (2015) B. Basu et al. CLINICAL CANCER RESEARCH
- A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma
- (2015) Ravindran Kanesvaran et al. Clinical Genitourinary Cancer
- Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors
- (2015) Matthew Zibelman et al. INVESTIGATIONAL NEW DRUGS
- The PI3K/AKT Pathway and Renal Cell Carcinoma
- (2015) Huifang Guo et al. Journal of Genetics and Genomics
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- The expanding role of mTOR in cancer cell growth and proliferation
- (2015) Marie Cargnello et al. MUTAGENESIS
- Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
- (2014) M. H. Voss et al. CLINICAL CANCER RESEARCH
- Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2014) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study
- (2014) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
- (2014) Alberto Ocana et al. PLoS One
- Renal cell carcinoma
- (2014) E. Jonasch et al. BMJ-British Medical Journal
- Application and interpretation of current autophagy inhibitors and activators
- (2013) Ya-ping Yang et al. ACTA PHARMACOLOGICA SINICA
- Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma
- (2013) M Santoni et al. BRITISH JOURNAL OF CANCER
- A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma
- (2013) Rhonda L. Bitting et al. Clinical Genitourinary Cancer
- Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
- (2013) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Reactive Oxygen Species via Redox Signaling to PI3K/AKT Pathway Contribute to the Malignant Growth of 4-Hydroxy Estradiol-Transformed Mammary Epithelial Cells
- (2013) Victor O. Okoh et al. PLoS One
- Autophagy Suppresses RIP Kinase-Dependent Necrosis Enabling Survival to mTOR Inhibition
- (2012) Kevin Bray et al. PLoS One
- Kidney cancer
- (2012) W. Marston Linehan et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
- (2011) Ana M. Molina et al. CANCER
- PTEN, pAKT, and pmTOR Expression and Subcellular Distribution in Primary Renal Cell Carcinomas and Their Metastases
- (2011) Martina Hager et al. CANCER INVESTIGATION
- mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets
- (2011) R. Watanabe et al. JOURNAL OF NUCLEAR MEDICINE
- Phosphoproteomic Analysis Identifies Grb10 as an mTORC1 Substrate That Negatively Regulates Insulin Signaling
- (2011) Y. Yu et al. SCIENCE
- Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
- (2010) Dorothy A. White et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Targeting mTOR in renal cell carcinoma
- (2010) Gary R. Hudes CANCER
- The role of the Atg1/ULK1 complex in autophagy regulation
- (2010) Noboru Mizushima CURRENT OPINION IN CELL BIOLOGY
- Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
- (2010) T Sato et al. ONCOGENE
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
- (2009) Robert J. Amato et al. CANCER
- Regulation of protein kinase Cδ downregulation by protein kinase Cε and mammalian target of rapamycin complex 2
- (2009) Alakananda Basu et al. CELLULAR SIGNALLING
- Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels
- (2009) D. Mahalingam et al. CLINICAL CANCER RESEARCH
- Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1
- (2009) C. C. Dibble et al. MOLECULAR AND CELLULAR BIOLOGY
- ULK-Atg13-FIP200 Complexes Mediate mTOR Signaling to the Autophagy Machinery
- (2009) Chang Hwa Jung et al. MOLECULAR BIOLOGY OF THE CELL
- Differential Responses of Human Regulatory T Cells (Treg) and Effector T Cells to Rapamycin
- (2009) Laura Strauss et al. PLoS One
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- HIF and reactive oxygen species regulate oxidative phosphorylation in cancer
- (2008) Eric Hervouet et al. CARCINOGENESIS
- VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma
- (2008) W. Marston Linehan et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2
- (2008) Alfredo Toschi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started